Class IIOngoingD-0571-2025
Drug recall · August 13, 2025
Xolair (omalizumab injection) recall
Why: CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Xolair (omalizumab injection), 150 mg/ml, 1 auto-injector, Rx only, Genentech, Inc, South San Francisco, CA 9408, NDC: 50242-215-55.
- Lots / codes
Lot: 3617756, Expires: 12/31/2025.
- Quantity
- 6 units
- Company
- Cardinal Health Inc., Dublin, OH
- Distribution
- Nationwide Within the U.S.
- Initiated
- July 30, 2025 · Voluntary: Firm initiated
- Classified
- August 7, 2025
- Reported
- August 13, 2025
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.